GBS to acquire drug screening firm Intelligent Fingerprinting

2020 09 08 18 51 2374 Business Handshake Meeting 400

GBS has inked a deal to acquire Intelligent Fingerprinting, a developer of point-of-care diagnostic screening technology for opioids and drugs of abuse.

The acquisition would enable the combination of Intelligent Fingerprinting's sweat-based drug screening technology with the GBS saliva-based glucose biosensor platform and manufacturing expertise, GBS said.

Intelligent Fingerprinting's drug screening system is a 10-minute test that analyzes fingerprint sweat to screen for recent drug use, consisting of a portable reader and single-use disposable cartridges.

Under terms of the agreement, GBS has until December 31 to evaluate and negotiate the transaction.

Page 1 of 6
Next Page